Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.282
-0.016 (-5.37%)
At close: Jan 17, 2025, 4:00 PM
0.280
-0.002 (-0.71%)
After-hours: Jan 17, 2025, 7:59 PM EST
Oragenics Employees
Oragenics had 5 employees as of December 31, 2023. The number of employees decreased by 1 or -16.67% compared to the previous year.
Employees
5
Change (1Y)
-1
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,993,245
Market Cap
3.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
OGEN News
- 5 weeks ago - Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - GlobeNewsWire
- 3 months ago - Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewsWire
- 3 months ago - Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces Pricing of Public Offering - GlobeNewsWire
- 5 months ago - Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - GlobeNewsWire
- 5 months ago - Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards - GlobeNewsWire